NCT02770391View on ClinicalTrials.gov

Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide acetate

Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3

DRUG

Apalutamide

Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.

PROCEDURE

Radical prostatectomy

Trial Locations (1)

44195

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02770391 - Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer | Biotech Hunter | Biotech Hunter